Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.61 |
| ▸ | TAAR1 | Q96RJ0 | 8/20 | 0.58 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | HTR2A | P28223 | 4/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | HTR3A | P46098 | 1/20 | 0.46 |
| ▸ | BACE1 | P56817 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7768079 | 0.83 | HRH3 (0.84) | HRH3HDAC8HDAC6 | |
| SCHEMBL1813157 | 0.82 | HRH3 (0.67) | HRH3ALDH1A1L3MBTL1HDAC8HDAC6 | |
| SCHEMBL4371629 | 0.82 | HRH3 (0.67) | HRH3KDM4EHDAC8HDAC6MAPT | |
| SCHEMBL28816939 | 0.80 | HRH3 (0.64) | HRH3KDM4EALDH1A1HDAC8HDAC6 | |
| Hydrochloric Acid SCHEMBL4461628 | 0.80 | HRH3 (0.64) | HRH3ALDH1A1L3MBTL1HDAC8HDAC6 | |
| Phenethylamine SCHEMBL2528177 | 0.78 | TAAR1 (0.70) | TAAR1CYP2A6CYP1A2HTR2AHTR1A | |
| SCHEMBL2876380 | 0.78 | HRH3 (0.61) | HRH3HDAC8HDAC6TDP1 | |
| SCHEMBL4277824 | 0.77 | HRH3 (0.58) | HRH3TAAR1CYP2A6CYP1A2HTR2A | |
| SCHEMBL1956276 | 0.77 | MAPT (0.64) | HRH3KDM4EALDH1A1L3MBTL1HDAC8 | |
| SCHEMBL12680476 | 0.77 | HRH3 (1.00) | HRH3TAAR1HDAC8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1534689-A1 | NOVEL CARBOXAMIDE COMPOUNDS HAVING AN MCH-ANTAGONISTIC EFFECT, MEDICAMENTS CONTAINING SAID COMPOUNDS, AND METHODS FOR THE PRODUCTION THEREOF | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-06-01 | — | — | EP | disclosed |
| US-20040242572-A1 | New carboxamide compounds having melanin concentrating hormone antagonistic activity, pharmaceutical preparations comprising these compounds and process for their manufacture | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-12-02 | — | — | US | disclosed |
| WO-2004024702-A1 | NOVEL CARBOXAMIDE COMPOUNDS HAVING AN MCH-ANTAGONISTIC EFFECT, MEDICAMENTS CONTAINING SAID COMPOUNDS, AND METHODS FOR THE PRODUCTION THEREOF | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242572-A1 | New carboxamide compounds having melanin concentrating hormone antagonistic activity, pharmaceutical preparations comprising these compounds and process for their manufacture | MCHR2, MCHR1, NPY1R | HRH3 254/4885TAAR1 141/4885CYP2A6 1696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.